Inactive Instrument

CTI BioPharma Corp.

Equities

CTIC

US12648L6011

Biotechnology & Medical Research

CTI BioPharma Corp. Announces Executive Changes, with Effect from March 20, 2017

February 27, 2017 at 01:30 am EST

CTI BioPharma Corp. announced the appointment of Adam Craig, M.D., Ph.D., as President and Chief Executive Officer (CEO) and member of the Board of Directors effective March 20, 2017. Dr. Craig succeeds Richard Love, interim President and CEO who will continue to serve on the company's Board of Directors.

Dr. Craig has over 20 years of experience in hematology, oncology and drug development in both the US and Europe. Dr. Craig has worked as an independent consultant providing strategic and operational advice and support to CTI BioPharma and other hematology/oncology biotechnology companies since 2016. Prior to consulting, Dr. Craig was Chief Medical Officer (CMO) and Executive Vice President of Development of Sunesis Pharmaceuticals from 2012 to 2016.

Dr. Craig is a Member of the Royal College of Physicians (UK) and undertook Post-Graduate Training in Pediatrics and Pediatric Oncology.

Latest news about CTI BioPharma Corp.

DRI Healthcare Trust Receives US$54.8 Million in Debt Repayment	23-06-26	MT
DRI Healthcare Trust Brief: Announcing US$54.8 Million Debt Repayment from CTI BioPharma Corp.	23-06-26	MT
DRI Healthcare Trust Announces USD 54.8 Million Debt Repayment from CTI Biopharma Corp	23-06-26	CI
Global markets live: Nvidia, IBM, Ford, Pfizer, Lucid Group...	23-06-26
Sobi Wraps Up $1.7 Billion Acquisition of CTI BioPharma	23-06-26	MT
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from NASDAQ Composite Index	23-06-26	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P Global BMI Index	23-06-26	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P Biotechnology Select Industry Index	23-06-26	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P TMI Index	23-06-26	CI
Swedish Orphan Biovitrum Completes Tender for CTI BioPharma	23-06-25	MT
Swedish Orphan Biovitrum AB (OM:SOBI) completed the acquisition of CTI BioPharma Corp. from a group of shareholders.	23-06-25	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Microcap Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2000 Dynamic Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000E Growth Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000E Value Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000E Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2500 Growth Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Completeness Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2000 Value Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2000 Growth Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2500 Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Microcap Value Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000 Value Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Comp Growth Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000 Growth Index	23-06-23	CI

Chart CTI BioPharma Corp.

Duration

Period

More charts

Company Profile

CTI BioPharma Corp. is a commercial biopharmaceutical company. It is focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers. Its commercially approved product, VONJO (pacritinib), is an oral kinase inhibitor with specificity for JAK2, mutant JAK2 form, IRAK1, ACVR1 (ALK2) and FLT3 for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. It is conducting the Phase III PACIFICA study of pacritinib in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, graft versus host disease (GvHD) and chronic lymphocytic leukemia (CLL) due to its inhibition of JAK2, IRAK1, FLT3, ACVR1 and CSF1R.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+21.74%	46.4B
IQVIA HOLDINGS INC.	-0.97%	41.75B
LONZA GROUP AG	+48.71%	41.37B
CELLTRION, INC.	-3.52%	29.71B
ICON PUBLIC LIMITED COMPANY	+11.12%	26.01B
ALNYLAM PHARMACEUTICALS, INC.	-19.37%	19.52B
MEDPACE HOLDINGS, INC.	+31.18%	12.43B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.04%	12.13B
BIO-TECHNE CORPORATION	+0.39%	12.18B

Other Biotechnology & Medical Research